| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.6M | -19.9% | -65.6% |
| SG&A Expense | $1.6M | +16.3% | +7.9% |
| Operating Income | -$4.2M | +9.2% | +53.7% |
| Net Income | -$8.2M | -8.8% | +27.1% |
| EPS (Basic) | -$0.13 | -8.3% | +27.8% |
| EPS (Diluted) | -$0.13 | -8.3% | +27.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $11.5M | -16.3% | -57.4% |
| Current Assets | $12.7M | -17.5% | -55.6% |
| Total Assets | $12.9M | -17.5% | -55.6% |
| Current Liabilities | $136.4M | +1166.4% | +440.2% |
| Total Liabilities | $136.4M | +2.8% | +12.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.8M | — | — |
| Financing Cash Flow | $14.2M | — | — |
| -$125.3M |
| -5.4% |
| -33.0% |